What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the CheckMate-9LA trial indicates that nivolumab combination improves overall and progression-free survival compared to standard platinum-doublet chemotherapy, with median overall survival of 15.6 months versus 10.9 months for standard chemotherapy. However, the lack of direct comparisons with other treatments and the uncertainty regarding the durability of the treatment effect limit the rating to A.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nivolumab combination are higher than what NICE considers acceptable for Healthcare resources, particularly for the subgroup with squamous NSCLC and PD-L1 TPS below 50%. The ICERs are above the typical thresholds, indicating low cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The ERG preferred a progression-based approach for utility values, which was supported by substantial data collected in CheckMate-9LA. This indicates moderate improvements in HRQoL, although the exact magnitude of these improvements remains uncertain due to the nature of the data.
Does the safety profile hold up for payers? — Safety and Adverse Effects
While nivolumab combination is likely to be less well tolerated than other chemo-immunotherapy combinations due to the dual immunotherapy approach, the overall safety profile remains acceptable with manageable adverse events. The evidence suggests that serious adverse events can be effectively managed.
Was the drug compared against what payers expect? — Comparator Selection
The comparators used in the analysis were appropriate, but the absence of direct head-to-head evidence with key alternatives like pembrolizumab plus pemetrexed and platinum chemotherapy raises concerns about the robustness of the indirect comparisons.
Is the population defined the way payers need it? — Patient Population and Subgroups
The clinical trials included populations that generally reflect those who would receive treatment in Healthcare practice, with considerations for relevant subgroups based on histology and PD-L1 status. This broad representation supports a strong rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab combination can be integrated into existing care pathways with minor adjustments, as it aligns with current treatment practices for untreated metastatic NSCLC. The need for some additional management for adverse events is noted but does not significantly disrupt integration.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of nivolumab combination are significant, raising concerns about budget impact. The estimates suggest a high resource burden, which may necessitate restrictions on use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from a Phase 3 RCT (CheckMate-9LA), which is robust, although there are some methodological concerns regarding indirect comparisons. Overall, the quality of evidence is strong.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and cost-effectiveness of nivolumab combination, particularly in relation to its durability and the impact of subsequent therapies. This uncertainty may restrict its use.
